Prevalence of Homebound 22 Percent in National Medicare Advantage Plan
Medically reviewed by drugclasses.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 12, 2024 -- In a national Medicare Advantage (MA) plan, the prevalence of homebound is 22 percent, and homebound status is independently associated with increased health service use and mortality, according to a study published online Aug. 13 in the Annals of Internal Medicine.
Bruce Leff, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues examined the prevalence, characteristics, predictors, health service use, and mortality outcomes of homebound beneficiaries of a national MA plan (2,435,519 Humana MA beneficiaries) in 2022. Homebound status was assessed via in-home assessment and categorized as homebound, semi-homebound, and not homebound.
The researchers found that the overall prevalence of homebound beneficiaries was 22.0 percent in 2022 (8.4 percent homebound; 13.6 percent semi-homebound). Homebound status was predicted by female sex, low-income status or dual eligibility for Medicaid and Medicare, dementia, and moderate-to-severe frailty in adjusted models (odds ratios, 1.36, 1.56, 2.36, and 4.32, respectively). Increased odds of any emergency department visit, any inpatient hospital admission, any skilled nursing-facility admission, and death were seen in association with homebound status in a multivariable logistic regression (odds ratios, 1.14, 1.44, 2.18, and 2.55, respectively).
"In the context of MA, homebound persons should be of special interest because frail older adults account for more than half of all preventable costs among Medicare beneficiaries," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2024
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of drugclasses.com in your inbox.